Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a randomized controlled trial.

The researchers examined the effects of 2 treatment strategies on the progression of secondary hyperparathyroidism using measurements of the nonsuppressible component of calcium-regulated PTH secretion as an index of parathyroid mass.

Why It Was Studied

Parathyroid gland function is affected adversely by tissue hyperplasia and gland enlargement in hyperparathyroidism.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The participants were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

Everyone knew when Parathyroid Hormone (PTH 1-84) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

PubMed files the paper under topics including Calcitriol, Cinacalcet, Disease Progression, Hyperparathyroidism, Secondary, Naphthalenes, Parathyroid Glands and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized and open-label study of Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.